Literature DB >> 15980873

Electrophysiological and haemodynamic effects of endothelin ETA and ETB receptors in normal and ischaemic working rabbit hearts.

Christopher McCabe1, Martin N Hicks, Kathleen A Kane, Cherry L Wainwright.   

Abstract

The aims of this study were to determine if endothelin-1 (ET-1) under normal and ischaemic conditions exhibits a direct arrhythmogenic effect that is independent of its ability to cause coronary vasoconstriction, and to determine the contribution of the ET(A) and ET(B) receptor subtype. ET(A/B) (with ET-1) and ET(A) (ET-1 in the presence of BQ-788) receptor activation resulted in a significant reduction in both epi- and endocardial monophasic action potential duration (MAPD(90)). ET(A) receptor activation reduced both epi- and endocardial effective refractory period (ERP). This MAPD(90) and ERP shortening were associated with a reduction in coronary flow, myocardial contractility and induction of ventricular fibrillation (VF) during ERP measurement. The ET(B) agonist sarafotoxin (S6c) had no marked, or concentration-dependent, effect on MAPD(90), ERP, myocardial contractility or induction of arrhythmias. Neither ET-1 nor S6c, given prior to coronary artery occlusion, significantly changed the ischaemia-induced dispersion of MAPD(90), ERP or the % incidence of VF. In conclusion, neither ET(A) nor ET(B) receptor stimulation has a direct arrhythmogenic effect in isolated rabbit hearts under normal or ischaemic conditions. The ET-1-induced arrhythmogenic effect observed in nonischaemic hearts is likely to be the result of the associated coronary vasoconstriction caused by ET(A) receptor stimulation resulting in myocardial ischaemia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15980873      PMCID: PMC1576251          DOI: 10.1038/sj.bjp.0706304

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  31 in total

Review 1.  Functional, structural, and dynamic basis of electrical heterogeneity in healthy and diseased cardiac muscle: implications for arrhythmogenesis and anti-arrhythmic drug therapy.

Authors:  R Wolk; S M Cobbe; M N Hicks; K A Kane
Journal:  Pharmacol Ther       Date:  1999-11       Impact factor: 12.310

2.  Regional electrophysiological effects of left ventricular hypertrophy in isolated rabbit hearts under normal and ischaemic conditions.

Authors:  R Wolk; K P Sneddon; J Dempster; K A Kane; S M Cobbe; M N Hicks
Journal:  Cardiovasc Res       Date:  2000-10       Impact factor: 10.787

3.  Mechanism of endothelin-induced malignant ventricular arrhythmias in dogs.

Authors:  B Merkely; L Gellér; M Tóth; O Kiss; V Kékesi; F Solti; T Vecsey; F Horkay; J Tenczer; A Juhász-Nagy
Journal:  J Cardiovasc Pharmacol       Date:  1998       Impact factor: 3.105

4.  Electrophysiological effects of intrapericardial infusion of endothelin-1.

Authors:  L Gellér; B Merkely; I Szokodi; T Szabó; T Vecsey; A Juhász-Nagy; M Tóth; F Horkay
Journal:  Pacing Clin Electrophysiol       Date:  1998-01       Impact factor: 1.976

5.  Investigating the dual nature of endothelin-1: ischemia or direct arrhythmogenic effect?

Authors:  T Szabó; L Gellér; B Merkely; L Selmeci; A Juhász-Nagy; F Solti
Journal:  Life Sci       Date:  2000-05-19       Impact factor: 5.037

6.  Ventricular arrhythmias induced by endothelin-1 or by acute ischemia: a comparative analysis using three-dimensional mapping.

Authors:  R Becker; B Merkely; A Bauer; L Gellér; L Fazekas; K D Freigang; F Voss; J C Senges; W Kuebler; W Schoels
Journal:  Cardiovasc Res       Date:  2000-01-14       Impact factor: 10.787

7.  Endothelin-A-receptor antagonist LU 135.252 inhibits the formation of ventricular arrhythmias caused by intrapericardial infusion of endothelin-1.

Authors:  O Kiss; L Gellér; B Merkely; T Szabó; M Raschack; L Seres; E Zima; A Juhász-Nagy; F Horkay
Journal:  J Cardiovasc Pharmacol       Date:  2000-11       Impact factor: 3.105

8.  The selective endothelin-A-receptor antagonist LU 135.252 inhibits the direct arrhythmogenic action of endothelin-1.

Authors:  B Merkely; T Szabó; L Gellér; O Kiss; F Horkay; M Raschack; A Juhász-Nagy
Journal:  J Cardiovasc Pharmacol       Date:  2000-11       Impact factor: 3.105

9.  Sarafotoxin 6c protects against ischaemia-induced cardiac arrhythmias in vivo and in vitro in the rat.

Authors:  T R Crockett; I Sharif; K A Kane; C L Wainwright
Journal:  J Cardiovasc Pharmacol       Date:  2000-11       Impact factor: 3.105

10.  Endothelin(A) receptor subtype mediates endothelin-induced contractility in left ventricular cardiomyocytes isolated from rabbit myocardium.

Authors:  E J Kelso; B J McDermott; B Silke; J P Spiers
Journal:  J Pharmacol Exp Ther       Date:  2000-09       Impact factor: 4.030

View more
  1 in total

Review 1.  Do endothelin receptor antagonists have an antiarrhythmic potential during acute myocardial infarction? Evidence from experimental studies.

Authors:  Dimitrios L Oikonomidis; Giannis G Baltogiannis; Theofilos M Kolettis
Journal:  J Interv Card Electrophysiol       Date:  2010-06-08       Impact factor: 1.900

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.